1 follower
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Their goal is to improve the response rate of patients to current and future immunotherapy medicines.
Industries
Headquarters
Stage
Employees
Links
Charles McDermott
View all
8 members
6 members
4 members
3 members
Dyno Therapeutics
3 followers
NotCo
Biogen
91 followers
Vertex Pharmaceuticals
33 followers
Seres Therapeutics
Explore more companies